المؤلفون: Laura Kowalczuk, Francine Behar-Cohen, Richard F. Spaide, Alejandra Daruich, Alexandre Matet, Ali Dirani, Irmela Mantel, Aude Ambresin, Natacha Turck

المصدر: Retina (Philadelphia, Pa.)
Retina, vol. 37, no. 12, pp. 2226-2237
Retina, Vol. 37, No 12 (2017) pp. 2226-2237

مصطلحات موضوعية: Male, Placental growth factor, retina, Time Factors, Visual acuity, genetic structures, Drug Resistance, Visual Acuity, Angiogenesis Inhibitors, chemistry.chemical_compound, 0302 clinical medicine, Original Study, Aged, Angiogenesis Inhibitors/administration & dosage, Bevacizumab/administration & dosage, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Intravitreal Injections, Middle Aged, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, Recombinant Fusion Proteins/administration & dosage, Retina/pathology, Retinal Telangiectasis/diagnosis, Retinal Telangiectasis/drug therapy, Retrospective Studies, Tomography, Optical Coherence/methods, Treatment Outcome, Macular telangiectasia, Aflibercept, macular telangiectasia, aflibercept, General Medicine, Diabetic retinopathy, 3. Good health, Bevacizumab, Vascular endothelial growth factor, 030220 oncology & carcinogenesis, medicine.symptom, Tomography, Optical Coherence, medicine.drug, medicine.medical_specialty, Recombinant Fusion Proteins, 03 medical and health sciences, Ophthalmology, medicine, ddc:576, business.industry, medicine.disease, eye diseases, Surgery, Receptors, Vascular Endothelial Growth Factor, chemistry, 030221 ophthalmology & optometry, Retinal Telangiectasis, sense organs, Ranibizumab, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152971000b9e76158e1f8fda4a9d0b7d
https://doi.org/10.1097/iae.0000000000001424

المؤلفون: Ciara Bergin, Irmela Mantel, Parmis Parvin, Sophie de Massougnes, Marta Zola, Ali Dirani

المصدر: Retina, vol. 39, no. 5, pp. 906-917

مصطلحات موضوعية: medicine.medical_specialty, genetic structures, business.industry, Incidence (epidemiology), Macular atrophy, General Medicine, Macular degeneration, medicine.disease, eye diseases, Ophthalmology, Regimen, medicine, sense organs, Dosing, Ranibizumab, Risk factor, business, medicine.drug, Aflibercept, Aged, Angiogenesis Inhibitors/administration & dosage, Angiogenesis Inhibitors/adverse effects, Atrophy/chemically induced, Atrophy/diagnosis, Atrophy/epidemiology, Disease Progression, Dose-Response Relationship, Drug, Female, Fluorescein Angiography, Fundus Oculi, Humans, Incidence, Intravitreal Injections, Macula Lutea/drug effects, Macula Lutea/pathology, Male, Prognosis, Prospective Studies, Ranibizumab/administration & dosage, Ranibizumab/adverse effects, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/adverse effects, Risk Factors, Switzerland/epidemiology, Tomography, Optical Coherence, Visual Acuity, Wet Macular Degeneration/diagnosis, Wet Macular Degeneration/drug therapy

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b82ce6d7f1abe3bf1d6256ea32c6e37e
https://serval.unil.ch/resource/serval:BIB_160E4E5271F0.P001/REF.pdf